| 【英語タイトル】Global Infertility Drugs Market Size study & Forecast, by Drug Class (Gonadotrophins, Aromatase Inhibitors, Selective Estrogen Receptor Modulators (SERMs), Biguanides, and Other Drug Classes), End User (Male and Female), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Other Distribution Channels), and Regional Analysis, 2022-2029
|
 | ・商品コード：BZW22DV123
・発行会社（調査会社）：Bizwit Research & Consulting
・発行日：2022年10月8日
・ページ数：約200
・レポート言語：英語
・レポート形式：PDF
・納品方法：Eメール（受注後3営業日）
・調査対象地域：アメリカ、カナダ、イギリス、ドイツ、フランス、スペイン、イタリア、中国、インド、日本、オーストラリア、韓国、ブラジル、メキシコ、中東
・産業分野：医薬品
|
◆販売価格オプション
（消費税別）
※販売価格オプションの説明
※お支払金額：換算金額（日本円）＋消費税
※納期：即日〜2営業日（3日以上かかる場合は別途表記又はご連絡）
※お支払方法：納品日＋5日以内に請求書を発行・送付（請求書発行日より2ヶ月以内に銀行振込、振込先：三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能）
|
Bizwit Research社は、2021年におよそXX億ドルであった世界の不妊治療薬市場規模が、2022年から2029年の間に6.5％以上成長すると予測しています。当調査資料は、不妊治療薬の世界市場を総合的に調査・分析し、エグゼクティブサマリー、市場定義・範囲、市場動向、産業分析、リスク分析（新型コロナウイルス感染症の影響）、薬剤分類別（ゴナドトロフィン、アロマターゼ阻害剤、選択的エストロゲン受容体モジュレーター（SERM）、ビグアニド、その他）分析、エンドユーザー別（男性、女性）分析、流通チャネル別（病院薬局、小売薬局、その他）分析、地域別（北米、ヨーロッパ、アジア太平洋、中南米、その他地域）分析、競争分析、調査プロセスなど、以下の構成でまとめております。なお、当書には、Abbott Laboratories、Ferring Pharmaceuticals Inc.、Merck KGaA、Pfizer Inc.、Novartis International AG、Bayer AG、Theramex、Mankind Pharma、Teva Pharmaceuticals Industries、Livzonなどの企業情報が含まれています。
・エグゼクティブサマリー
・市場定義・範囲
・市場動向
・産業分析
・リスク分析（新型コロナウイルス感染症の影響）
・世界の不妊治療薬市場規模：薬剤分類別
- ゴナドトロフィンの市場規模
- アロマターゼ阻害剤の市場規模
- 選択的エストロゲン受容体モジュレーター（SERM）の市場規模
- ビグアニドの市場規模
- その他薬剤の市場規模
・世界の不妊治療薬市場規模：エンドユーザー別
- 男性における市場規模
- 女性における市場規模
・世界の不妊治療薬市場規模：流通チャネル別
- 病院薬局チャネルの市場規模
- 小売薬局チャネルの市場規模
- その他流通チャネルの市場規模
・世界の不妊治療薬市場規模：地域別
- 北米の不妊治療薬市場規模
- ヨーロッパの不妊治療薬市場規模
- アジア太平洋の不妊治療薬市場規模
- 中南米の不妊治療薬市場規模
- その他地域の不妊治療薬市場規模
・競争分析
・調査プロセス |
❖ レポートの概要 ❖
Global Infertility Drugs Market is valued approximately USD XX billion in 2021 and is anticipated to grow with a healthy growth rate of more than 6.5% over the forecast period 2022-2029. The term “infertility medicines” refers to a group of pharmaceuticals that are used to treat infertility and improve a person’s reproductive health. They can be swallowed or administered intravenously. Gonadotrophins, dopamine agonists, aromatase inhibitors, biguanides, ovulatory stimulants, selective oestrogen receptor modulators (SERMs), and tricyclic antidepressants are a few of the medications that are frequently used to treat infertility. The infertility drugs market is anticipated to expand significantly owing to upsurge in Healthcare Awareness along with increasing aging female population and growing prevalence of stress and life-style disorders among men and women.
The National Center for Drug Abuse Statistics found that during the COVID-19 lockdowns, almost 60.0% of Americans increased their alcohol intake. In a similar vein, according to a study issued by the World Health Organization in 2021, China had more than 300.0 million smokers, or over one-third of the world’s population at the time. In China, there were around 26.6% of adults who smoked who were 15 years of age or older. One of the major contributors to hormonal imbalance, polycystic ovarian disease, and weight problems, which have an immediate influence on the embryo and might cause infertility concerns, is a healthy lifestyle. On the other side, over the past 16 years, the percentage of males with a normal total motile sperm count has decreased by around 10%. The evidence is clear: Men today generate less and less healthy sperm than in the past. However, strict regulatory structure that impedes the approval of products stifles market growth throughout the forecast period of 2022-2029.
The key regions considered for the Global Infertility Drugs Market study includes Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America is leading the overall market share owing to menopausal disorders and high concentration of market players or manufacturer’s presence. However, Asia Pacific expected to be the fastest growing region owing to rising healthcare expenditures and initiatives by the government to increase the availability of the infertility treatment in the developing nations.
Major market player included in this report are:
Abbott Laboratories
Ferring Pharmaceuticals Inc.
Merck KGaA
Pfizer Inc.
Novartis International AG
Bayer AG
Theramex
Mankind Pharma
Teva Pharmaceuticals Industries
Livzon
Recent Developments in the Market:
In order to sell Genea Biomedx’s (Australia) fertility products in the US and Canada, Genea Biomedx (Australia) partnered with Hamilton Thorne in 2020.
In August 2021, Merck introduced Pergoveris Pen in India for the treatment of infertility. The Pergoveris Pen is the first item to ever include both recombinant follicle-stimulating hormone and recombinant luteinizing hormone in a ready-to-use, IVF specialist-prescribed device. A pen with bulk technology that has received international approval offers infertile couples a more secure self-service infertility option.
Global Infertility Drugs Market Report Scope:
Historical Data 2019-2020-2021
Base Year for Estimation 2021
Forecast period 2022-2029
Report Coverage Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
Segments Covered Drug class, End User, Distribution Channel, Region
Regional Scope North America; Europe; Asia Pacific; Latin America; Rest of the World
Customization Scope Free report customization (equivalent up to 8 analyst’s working hours) with purchase. Addition or alteration to country, regional & segment scope*
The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.
The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:
By Drug Class:
Gonadotrophins
Aromatase Inhibitors
Selective Estrogen Receptor Modulators (SERMs)
Biguanides
Other Drug Classes
By End User:
Male
Female
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Other Distribution Channels
By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Rest of the World
Chapter 1. Executive Summary
1.1. Market Snapshot
1.2. Global & Segmental Market Estimates & Forecasts, 2019-2029 (USD Billion)
1.2.1. Infertility Drugs Market, by region, 2019-2029 (USD Billion)
1.2.2. Infertility Drugs Market, by Drug Class, 2019-2029 (USD Billion)
1.2.3. Infertility Drugs Market, by End User, 2019-2029 (USD Billion)
1.2.4. Infertility Drugs Market, by Distribution Channel, 2019-2029 (USD Billion)
1.3. Key Trends
1.4. Estimation Methodology
1.5. Research Assumption
Chapter 2. Global Infertility Drugs Market Definition and Scope
2.1. Objective of the Study
2.2. Market Definition & Scope
2.2.1. Scope of the Study
2.2.2. Industry Evolution
2.3. Years Considered for the Study
2.4. Currency Conversion Rates
Chapter 3. Global Infertility Drugs Market Dynamics
3.1. Infertility Drugs Market Impact Analysis (2019-2029)
3.1.1. Market Drivers
3.1.1.1. Upsurge in Healthcare Awareness along with Increasing Aging Female Population
3.1.1.2. Growing Prevalence of Stress and Life-style Disorders among Men and Women
3.1.2. Market Challenges
3.1.2.1. Strict Regulatory Structure that Impedes the Approval of Products
3.1.3. Market Opportunities
3.1.3.1. Rising incidences of infertility and miscarriage
3.1.3.2. Increasing public funding for developing these drugs
Chapter 4. Global Infertility Drugs Market Industry Analysis
4.1. Porter’s 5 Force Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.2. Futuristic Approach to Porter’s 5 Force Model (2019-2029)
4.3. PEST Analysis
4.3.1. Political
4.3.2. Economical
4.3.3. Social
4.3.4. Technological
4.4. Investment Adoption Model
4.5. Analyst Recommendation & Conclusion
4.6. Top investment opportunity
4.7. Top winning strategies
Chapter 5. Risk Assessment: COVID-19 Impact
5.1. Assessment of the overall impact of COVID-19 on the industry
5.2. Pre COVID-19 and post COVID-19 Market scenario
Chapter 6. Global Infertility Drugs Market, by Drug Class
6.1. Market Snapshot
6.2. Global Infertility Drugs Market by Drug Class, Performance – Potential Analysis
6.3. Global Infertility Drugs Market Estimates & Forecasts by Drug Class 2019-2029 (USD Billion)
6.4. Infertility Drugs Market, Sub Segment Analysis
6.4.1. Gonadotrophins
6.4.2. Aromatase Inhibitors
6.4.3. Selective Estrogen Receptor Modulators (SERMs)
6.4.4. Biguanides
6.4.5. Other Drug Classes
Chapter 7. Global Infertility Drugs Market, by End User
7.1. Market Snapshot
7.2. Global Infertility Drugs Market by End User, Performance – Potential Analysis
7.3. Global Infertility Drugs Market Estimates & Forecasts by End User 2019-2029 (USD Billion)
7.4. Infertility Drugs Market, Sub Segment Analysis
7.4.1. Male
7.4.2. Female
Chapter 8. Global Infertility Drugs Market, by Distribution Channel
8.1. Market Snapshot
8.2. Global Infertility Drugs Market by Distribution Channel, Performance – Potential Analysis
8.3. Global Infertility Drugs Market Estimates & Forecasts by Distribution Channel 2019-2029 (USD Billion)
8.4. Infertility Drugs Market, Sub Segment Analysis
8.4.1. Hospital Pharmacies
8.4.2. Retail Pharmacies
8.4.3. Other Distribution Channels
Chapter 9. Global Infertility Drugs Market, Regional Analysis
9.1. Infertility Drugs Market, Regional Market Snapshot
9.2. North America Infertility Drugs Market
9.2.1. U.S. Infertility Drugs Market
9.2.1.1. Drug Class breakdown estimates & forecasts, 2019-2029
9.2.1.2. End User breakdown estimates & forecasts, 2019-2029
9.2.1.3. Distribution Channel breakdown estimates & forecasts, 2019-2029
9.2.2. Canada Infertility Drugs Market
9.3. Europe Infertility Drugs Market Snapshot
9.3.1. U.K. Infertility Drugs Market
9.3.2. Germany Infertility Drugs Market
9.3.3. France Infertility Drugs Market
9.3.4. Spain Infertility Drugs Market
9.3.5. Italy Infertility Drugs Market
9.3.6. Rest of Europe Infertility Drugs Market
9.4. Asia-Pacific Infertility Drugs Market Snapshot
9.4.1. China Infertility Drugs Market
9.4.2. India Infertility Drugs Market
9.4.3. Japan Infertility Drugs Market
9.4.4. Australia Infertility Drugs Market
9.4.5. South Korea Infertility Drugs Market
9.4.6. Rest of Asia Pacific Infertility Drugs Market
9.5. Latin America Infertility Drugs Market Snapshot
9.5.1. Brazil Infertility Drugs Market
9.5.2. Mexico Infertility Drugs Market
9.6. Rest of The World Infertility Drugs Market
Chapter 10. Competitive Intelligence
10.1. Top Market Strategies
10.2. Company Profiles
10.2.1. Teva Pharmaceuticals Industries
10.2.1.1. Key Information
10.2.1.2. Overview
10.2.1.3. Financial (Subject to Data Availability)
10.2.1.4. Product Summary
10.2.1.5. Recent Developments
10.2.2. Abbott Laboratories
10.2.3. Mankind Pharma
10.2.4. Merck KGaA
10.2.5. Ferring Pharmaceuticals Inc.
10.2.6. Novartis International AG
10.2.7. Livzon
10.2.8. Pfizer Inc.
10.2.9. Theramex
10.2.10. Bayer AG
Chapter 11. Research Process
11.1. Research Process
11.1.1. Data Mining
11.1.2. Analysis
11.1.3. Market Estimation
11.1.4. Validation
11.1.5. Publishing
11.2. Research Attributes
11.3. Research Assumption
